Terms: = Kidney tumors AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
16 results:
1. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract] [Full Text] [Related]
2. The emerging role of nf2 alterations in new and established subtypes of renal cell carcinoma.
Paintal A; Antic T
Hum Pathol; 2023 Mar; 133():87-91. PubMed ID: 35705112
[TBL] [Abstract] [Full Text] [Related]
3. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
[TBL] [Abstract] [Full Text] [Related]
4. Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis.
Piszczek R; Nowak Ł; Krajewski W; Chorbińska J; Poletajew S; Moschini M; Kaliszewski K; Zdrojowy R
World J Surg Oncol; 2021 Apr; 19(1):129. PubMed ID: 33882936
[TBL] [Abstract] [Full Text] [Related]
5. Development of novel acn (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
[TBL] [Abstract] [Full Text] [Related]
6. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
[TBL] [Abstract] [Full Text] [Related]
7. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract] [Full Text] [Related]
9. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.
Wang J; Papanicolau-Sengos A; Chintala S; Wei L; Liu B; Hu Q; Miles KM; Conroy JM; Glenn ST; Costantini M; Magi-Galluzzi C; Signoretti S; Choueiri T; Gallucci M; Sentinelli S; Fazio VM; Poeta ML; Liu S; Morrison C; Pili R
Oncotarget; 2016 May; 7(21):29901-15. PubMed ID: 27144525
[TBL] [Abstract] [Full Text] [Related]
10. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
[TBL] [Abstract] [Full Text] [Related]
11. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract] [Full Text] [Related]
12. Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin.
Wei EY; Chen YB; Hsieh JJ
BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26494726
[TBL] [Abstract] [Full Text] [Related]
13. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
van Besien K; Stock W; Rich E; Odenike O; Godley LA; O'Donnell PH; Kline J; Nguyen V; Del Cerro P; Larson RA; Artz AS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):913-21. PubMed ID: 22079470
[TBL] [Abstract] [Full Text] [Related]
14. Does antineoplasm treatment decrease the glomerular filtration rate in children?
Stefanowicz J; Owczuk R; Sierota D; Kaczorowska-Hać B; Balcerska A
Kidney Blood Press Res; 2009; 32(3):194-9. PubMed ID: 19521109
[TBL] [Abstract] [Full Text] [Related]
15. A multinomial Phase II study of lonafarnib (sch 66336) in patients with refractory urothelial cancer.
Winquist E; Moore MJ; Chi KN; Ernst DS; Hirte H; North S; Powers J; Walsh W; Boucher T; Patton R; Seymour L
Urol Oncol; 2005; 23(3):143-9. PubMed ID: 15907712
[TBL] [Abstract] [Full Text] [Related]
16. Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials.
Umeda T; Niijima T
Cancer; 1986 Sep; 58(6):1231-5. PubMed ID: 3742449
[TBL] [Abstract] [Full Text] [Related]
